J Bone Miner Res 1998; 13:1431–1438 063 Yes 2 years 100 66.1 Bell NH, et al. J Clin Endocrinol Metab 2002; 87:2792–2797 072 Yes 2 years 100 61.3 Bone HG, et al. J Clin Endocrinol Metab click here 2000; 85:720–726 082 Yes 1 year 69.5 54.7 Saag KG, et al. N
Engl J Med 1998; 339:292–299 083 Yes 1 year 67.2 56.0 Saag KG, et al. N Engl J Med 1998; 339:292–299 087 Yes 6 months 100 78.5 Greenspan SL, et al. Ann PD-1/PD-L1 targets Intern Med 2002;
136:742–746 088 Yes 6 months 100 66.2 Bonnick SL, et al. Curr Med Res Opin 2007; 23:1341–1349 (INPACT) 095 Yes 1 year 43.9 46.0 van der Poest CE, et al. J Bone Miner Res 2002; 17:2247–2255 096 Yes 2 years 0 62.7 Orwoll E, et al. N Engl J Med 2000; 343:604–610 097 Yes 1 year 100 61.7 Lindsay R, et al. J Clin Endocrinal Metab 1999; 84:3076–3081 (FACET) 104 Yes 1 year 100 64 Downs RW Jr, et al. J Clin Endocrinol Metab 2000; 85:1783–1788 LY2835219 ic50 (FOCAS) 109 Yes 1 year 100 65 Data on file (inFOCAS) 112 Yes 2 years 51 50.5 Jeffcoat MK, et al. In: Davidovitch Z, Norton LA (eds) Biological mechanisms of tooth movement and craniofacial adaptation. Harvard Society for the Advancement of Orthodontics, Boston, 1996:365–373 117 Yes C-X-C chemokine receptor type 7 (CXCR-7) 6 months 36.6 63 Rubash H, et al. 50th annual meeting of the Orthopaedic Research Society [Abstract]. Transactions 2004; 29:1942 159 Yes 1 year 100 69.2 Hosking D, et al. Curr Med Res Opin 2003; 19:383–394 162 Yes 12 weeks 92.4 66.7 Greenspan S, et al. Mayo
Clin Proc 2002; 77:1044–1052 165 Yes 1 year 0 66.1 Miller PD, et al. Clin Drug Invest 2004; 24:333–341 193 Yes 1 year 58.4 52.9 Stoch S, et al. J Rheumatol 2009; 36:1705–1714 219 Yes 6 months 100 65.2 Cryer B, et al. Am J Geriatr Pharmacother 2005; 3:127–136 (OASIS) 901 Yes 1 year 100 62.8 Pols HA, et al. Osteoporos Int 1999; 9:461–468 (FOSIT) 902 Yes 1 year 100 57.3 Ascott-Evans BH, et al. Arch Intern Med 2003; 163:789–794 904 Yes 12 weeks 94.2 63.6 Eisman JA, et al. Curr Med Res Opin 2004; 20:699–705 056 No Paget’s disease 6 months 34.8 69.0 Siris E, et al. J Clin Endocrinol Metab 1996; 81:961–967 059 No Paget’s disease: alendronate dose above allowable range 6 months 43.6 69.9 Reid IR, et al. Am J Med 1996; 101:341–348 118 No No placebo comparator 2 years 100 66.5 Rizzoli R, et al. J Bone Miner Res 2002; 17:1988–1996 119 No No placebo comparator 1 year 100 56.2 Luckey MM, et al. Obstet Gynecol 2003; 101:711–721 189 No No placebo comparator 1 year 100 64.2 Luckey M, et al.